Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma
暂无分享,去创建一个
R. Smoot | J. Tomlinson | Binbin Li | Hannah E. Stumpf | S. Ilyas | E. Loeuillard | Haidong Dong | Jessica Willhite | Vernadette A. Simon | Jingchun Yang | Rondell P. Graham | Fred Rakhshan Rohakhtar
[1] G. Gores,et al. Cholangiocarcinoma — novel biological insights and therapeutic strategies , 2023, Nature Reviews Clinical Oncology.
[2] S. Barry,et al. Therapeutic targeting of tumour myeloid cells , 2023, Nature Reviews Cancer.
[3] X. Wang,et al. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer , 2022, Nature Communications.
[4] R. Bernards,et al. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis , 2022, Nature Cancer.
[5] Chun Jimmie Ye,et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis , 2022, Cell reports.
[6] Ruibin Xi,et al. Publisher Correction: Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma , 2022, Nature Communications.
[7] M. Rebelatto,et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. , 2022, The lancet. Gastroenterology & hepatology.
[8] Martin S. Taylor,et al. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma , 2022, Cancer research.
[9] S. Gottschalk,et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer , 2021, Journal for ImmunoTherapy of Cancer.
[10] J. Yeh,et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity , 2021, Gut.
[11] Shannon K. Boi,et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer , 2020, Journal for ImmunoTherapy of Cancer.
[12] V. Ivanisenko,et al. Pharmacological targeting of c-FLIPL and Bcl-2 family members promotes apoptosis in CD95L-resistant cells , 2020, Scientific Reports.
[13] P. Krebs,et al. The multifaceted role of TRAIL signaling in cancer and immunity , 2020, The FEBS journal.
[14] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[15] Chen Wang,et al. Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma. , 2020, The Journal of clinical investigation.
[16] E. Jaffee,et al. The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities , 2020, Nature Reviews Clinical Oncology.
[17] Hong Wang,et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies , 2020, International journal of cancer.
[18] D. Calvisi,et al. Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis. , 2019, Journal of hepatology.
[19] Jonathan M. Hernandez,et al. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. , 2019, Cancer cell.
[20] C. Ries,et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response , 2019, Nature Cell Biology.
[21] S. Bicciato,et al. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes , 2018, Nature Communications.
[22] Zev J. Gartner,et al. DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors , 2018, bioRxiv.
[23] D. Gabrilovich,et al. Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.
[24] G. Gores,et al. YAP-associated chromosomal instability and cholangiocarcinoma in mice , 2017, Oncotarget.
[25] Y. Shaked,et al. CCR5 Directs the Mobilization of CD11b+Gr1+Ly6Clow Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. , 2017, Cell reports.
[26] Bin Tean Teh,et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. , 2017, Cancer discovery.
[27] A. Chakravarthy,et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 , 2017, Molecular cell.
[28] Philippe Foubert,et al. PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.
[29] R. V. van Ginkel,et al. Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction , 2016, Oncoimmunology.
[30] Shannon M. White,et al. Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma , 2016, Oncogene.
[31] G. Gores,et al. IL‐33 facilitates oncogene‐induced cholangiocarcinoma in mice by an interleukin‐6‐sensitive mechanism , 2015, Hepatology.
[32] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[33] N. Hockstein,et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. , 2014, The Journal of clinical investigation.
[34] L. Boon,et al. Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells , 2014, Cancer Immunology, Immunotherapy.
[35] C. Meyer,et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.
[36] S. Fulda,et al. The dark side of TRAIL signaling , 2013, Cell Death and Differentiation.
[37] S. Markovic,et al. Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth , 2013, Oncoimmunology.
[38] G. Peters,et al. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family , 2013, Cell Death and Differentiation.
[39] A. Zhu,et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. , 2012, Cancer research.
[40] L. Norian,et al. Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy , 2012, PloS one.
[41] S. Bicciato,et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. , 2010, Immunity.
[42] H. Gollnick,et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis , 2008, Oncogene.
[43] L. Mariani,et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] I. Jeremias,et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.
[45] M. Smyth,et al. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.
[46] A. Tannapfel,et al. Mutations of p53 Tumor Suppressor Gene, Apoptosis, and Proliferation in Intrahepatic Cholangiocellular Carcinoma of the Liver , 2000, Digestive Diseases and Sciences.
[47] W. Reith,et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.
[48] E. Alnemri,et al. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. , 1999, Cancer research.
[49] J. Tschopp,et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.
[50] Henning Walczak,et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.
[51] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[52] Acknowledgments , 1993, Experimental Gerontology.
[53] G. Gores,et al. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. , 2006, American journal of physiology. Gastrointestinal and liver physiology.
[54] Michael Karin,et al. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. , 2005, The Journal of clinical investigation.